Generic Cancidas Availability
Cancidas is a brand name of caspofungin, approved by the FDA in the following formulation(s):
CANCIDAS (caspofungin acetate - injectable;iv (infusion))
Has a generic version of Cancidas been approved?
No. There is currently no therapeutically equivalent version of Cancidas available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Cancidas. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Aza cyclohexapeptide compounds
Patent 5,514,650
Issued: May 7, 1996
Inventor(s): Balkovec; James M. & Black; Regina M. & Bouffard; Frances A.
Assignee(s): Merck & Co., Inc.
Ceretain aza cyclohexapeptide compounds have been found to have superior antibiotic properties. Novel processes for their preparation are also described.Patent expiration dates:- July 26, 2015✓
- July 26, 2015
-
Antifungal compositions
Patent 5,952,300
Issued: September 14, 1999
Inventor(s): Nerurkar; Maneesh J. & Hunke; William A. & Kaufman; Michael J.
Assignee(s): Merck & Co., Inc.
The invention is a pharmaceutical composition for intravenous administration to a patient comprising a) a pharmaceutically effective amount of a compound having the formula ##STR1## and the pharmaceutically acceptable salts thereof; b) a pharmaceutically acceptable amount of an excipient such as a bulking agent effective to form a lyophilized cake; and c) a pharmaceutically acceptable amount of acetate buffer effective to provide a pH of between about 4 and 7.Patent expiration dates:- March 28, 2017✓
- September 28, 2017✓
- March 28, 2017
-
Antifungal compositions
Patent 6,136,783
Issued: October 24, 2000
Inventor(s): Neururkar; Maneesh J. & Kaufman; Michael J. & Hunke; William A.
Assignee(s): Merck & Co., Inc.
The invention is a pharmaceutical composition for intravenous administration to a patient comprising a) a pharmaceutically effective amount of a compound having the formula ##STR1## and the pharmaceutically acceptable salts thereof; b) a pharmaceutically acceptable amount of an excipient such as a bulking agent effective to form a lyophilized cake; and c) a pharmaceutically acceptable amount of acetate buffer effective to provide a pH of between about 4 and 7.Patent expiration dates:- March 28, 2017✓
- September 28, 2017✓
- March 28, 2017
More about Cancidas (caspofungin)
Consumer resources
Professional resources
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
